TP53 and neoplasm: In the MSKCC chemotherapy-treated cohort, the MGMT methylated group showed no significant prognostic effect of TP53 mutation (p > 0.05) (Figure 9A); however, within the MGMT unmethylated group, both other TP53 mutant and codon 273 mutant tumours were associated with a significantly increased OS (other vs. WT median survival: 84.2 mo.